IAG, Image Analysis Group is comprised of Image Analysis, Ltd., Image Analysis, Inc. and venture partners. Through our three divisions: Strategy, Trial Solutions and Bio-Partnering we support biotechnology and pharmaceutical companies developing new treatments to improve patients’ lives.
IAG’ strategic advisory board and management team leverage decades of therapeutic insights, core medical imaging expertise and outside-the-box thinking. We design clinical trials with optimal endpoints to prove novel drug efficacy, while focusing the resources.
IAG’ global clinical trial delivery team ensure reliable execution of clinical programs. Our operational efficiency is underpinned by our proprietary machine learning cloud based platform DYNAMIKA. It is an integral part of scalable data management and central image reading. Our streamlined operations improve ROI and increase the transparency of study performance.
Our independent Bio-Partnering division fuses a risk-sharing business model and an agile culture to accelerate novel drug development. We closely work with our venture partners and biotech executive management to optimize financial and operational outcomes.
OUR HISTORY BY OUR CEO
While studying for her PhD at Leeds, Olga Kubassova began work on commercialising her research. She was the first winner of the Sir Peter Thompson Enterprise Award, and ten years on her global business with HQ in London, UK and Philadelphia, USA is providing high-quality imaging services for clinical trials around the world. In this video, Olga talks about the encouragement she received in establishing the business, the fast growing team and endorsement from partners and clients, which include top 10 pharmacutical companies, innovative biotech and medtech players and IAG’s own portforlio companies.
Targeted market assessment, patented benchmarking libraries, analytics platform and the most comprehensive expert advisory board help our clients to formulate clear strategy and design the optimal trial for early go / no go decisions.
Integration of cloud platform, study-specific biomarkers with experience of IAG’ commercial and operational team ensures meeting your business objectives for growth or partnering, fast execution of projects and scientific credibility of the outcomes.
An independent investment division of IAG seeks to partner with biotech companies with promising compounds at early stages of clinical development or academics with IP ready for commercialization.
From the Technology Innovation to the Entrepreneur of the Year, IAG’s team, its founder-CEO and its industry disrupting technology platform DYNAMIKA won 22 awards since 2007. We share, with pride and thanks!
Since 2007, over 2000 articles were published to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.
ISO Quality Management System and SOPs audited by BSI and external partners as well as CE and FDA510K clearance for DYNAMIKA platform.
Combining our technologies and business advisory services with promising life science companies has yielded spectacular results over the past five years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words.